Abstract
Neuroendocrine neoplasms (NEN) are rare malignancies with a wide spectrum of metastatic potential which originate from the endocrine cells of the body and express somatostatin receptors. The (68)gallium somatostatin receptor positron emission tomography-computed tomography (PET/CT) technique is the most sensitive method of assessment of well-differentiated NENs and for the detection of cancer of unknown primary (CUP syndrome) NENs. Imaging with 18F-fluorodeoxyglucose (18F-FDG PET/CT) is indicated in poorly differentiated neuroendocrine carcinomas. The receptor-dependent imaging of NENs has a decisive impact on further management.
MeSH terms
-
Fluorodeoxyglucose F18
-
Gallium Radioisotopes
-
Gene Expression Regulation, Neoplastic / genetics
-
Humans
-
Molecular Imaging / methods*
-
Multimodal Imaging / methods*
-
Neoplasms, Unknown Primary / diagnosis
-
Neoplasms, Unknown Primary / genetics
-
Neoplasms, Unknown Primary / pathology
-
Neoplasms, Unknown Primary / surgery
-
Neuroendocrine Tumors / diagnosis*
-
Neuroendocrine Tumors / genetics
-
Neuroendocrine Tumors / pathology
-
Neuroendocrine Tumors / surgery*
-
Positron-Emission Tomography / methods*
-
Receptors, Somatostatin
-
Sensitivity and Specificity
-
Somatostatin
-
Tomography, X-Ray Computed / methods*
Substances
-
Gallium Radioisotopes
-
Receptors, Somatostatin
-
Fluorodeoxyglucose F18
-
Somatostatin